

EP 0 480 659 claims compounds of general formula (d),



(d)

wherein Z^2 inter alia may be carboxyl-C_1-C_{10}-alkyl-C= and Y may be substituted benzyl, said compounds being useful for the treatment of hyperuricemia.


WO 2005/040128 claims compounds of general formula (e),



(e)

said compounds being useful for the treatment of conditions such as pain, or an inflammatory, immunological, bone, neurodegenerative or renal disorder.

WO 01/38325 claims compounds of general formula (f),



(f)


wherein A is an aromatic ring and B is a nitrogen-containing 5-membered hetero ring which may further be substituted, said compounds having hypoglycemic and hypolipidemic activity.

SUMMARY

It is an objective of the embodiments disclosed herein~~present invention~~ to provide further compounds having CRTH2 antagonistic activity.

Preferably the compounds of the present disclosure~~invention~~ have enhanced chemical stability, enhanced pharmacokinetic properties (PK) and/or enhanced activity in a whole cell assay.

In a first aspect, there is provided pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof,



(I)

wherein

W is selected from hydroxycarbonyl and -C(O)-NH-S(O)$_2$-R^a, wherein R^a is selected from C_1-C_6-alkyl, C_1-C_6-haloalkyl, cyclopropyl, phenyl and tolyl;

L^1 is methylene, which is unsubstituted or carries 1 or 2 radicals selected independently from each other from hydroxy, halogen, C_1-C_6-alkyl, C_1-C_6-haloalkyl, C_1-C_6-alkoxy, C_1-C_6-haloalkoxy and C_3-C_8-cycloalkyl;

L^2 is methylene which is unsubstituted or carries 1 or 2 radicals selected independently from each other from C_1-C_4-alkyl and C_3-C_6-cycloalkyl or two of said radicals bound to the same carbon atom of L^2 together with said carbon atom form a 3- to 6-membered ring;

X is phen-1,4-ylene or pyridin-2,5-ylene, which are unsubstituted or carry 1, 2 or 3 radicals selected independently from each other from hydroxy, halogen, C_1-C_6-alkyl, C_1-C_6-haloalkyl, C_1-C_6-alkoxy, C_1-C_6-haloalkoxy and C_3-C_8-cycloalkyl;

L^3 is selected from -CH=CH-, -C≡C-, -CR^bR^c-CH(OH)-, -CR^bR^c-C(O)-, -CR^bR^c-O-, -CR^bR^c-NR^d-, -CR^bR^c-$S(O)_m$-, -CH(OH)-, -C(O)-, -C(O)-NR^d-, -O-, -NR^d-, -NR^d-C(O)-, -NR^dC(O)-O-, -NR^d-C(O)-NR^e-, -NR^d-$S(O)_n$-, -$S(O)_p$- and -$S(O)_q$-NR^d-, wherein m, n and p are 0, 1 or 2 and q is 1, or 2, and wherein

R^b and R^c are independently from each other selected from H, C_1-C_6-alkyl, C_3-C_8-cycloalkyl and wherein two radicals R^b and R^c bound to the same carbon atom together with said carbon atom may form a 3- to 8-membered ring, wherein said ring may contain 1 or 2 heteroatoms selected from O, N and S as ring member and wherein the ring members of said ring may optionally be independently substituted by hydroxy, halogen, C_1-C_6-alkyl, C_1-C_6-haloalkyl, C_1-C_6-alkoxy, C_1-C_6-haloalkoxy and C_3-C_8-cycloalkyl, and wherein

R^d and R^e independently from each other are H or C_1-C_6-alkyl;

Y is selected from C_3-C_8-cycloalkyl, C_3-C_8-cycloalkyl-C_1-C_6-alkyl, C_3-C_8-cycloalkyl-C_2-C_6-alkenyl, phenyl, phenyl-C_1-C_6-alkyl, phenyl-C_2-C_6-alkenyl, naphthyl, naphthyl-C_1-C_6-alkyl, naphthyl-C_2-C_6-alkenyl, heterocyclyl, heterocyclyl-C_1-C_6-alkyl and heterocyclyl-C_2-C_6-alkenyl, wherein the heterocyclyl moieties are selected from 5- to 7-membered heterocyclic radicals and 5- to10-membered, bicyclic heterocyclic radicals, containing one, two or three heteroatoms, selected from O, N and S as ring members, and wherein

the C_1-C_6-alkyl and C_2-C_6-alkenyl moieties in the aforementioned radicals Y are unsubstituted or carry at least one substituent selected from hydroxy,

halogen, cyano, nitro, C_1-C_6-alkoxy, C_1-C_6-haloalkoxy, C_1-C_6-alkylamino, di-C_1-C_6-alkylamino and C_1-C_6-alkylsulfonyl and wherein two of said substituents bound to the same carbon atom of the C_1-C_6-alkyl moieties together with said carbon atom may form a 3- to 8-membered ring, wherein said ring may contain 1 or 2 heteroatoms selected from O, N and S as ring member, and

wherein the C_3-C_8-cycloalkyl, phenyl, naphthyl or heterocyclyl moieties in the aforementioned radicals Y are unsubstituted or carry at least one substituent selected from hydroxy, halogen, cyano, nitro, SF_5, -C(O)NR^fR^g, C_1-C_6-alkyl, hydroxy-C_1-C_6-alkyl, C_1-C_6-alkoxy-C_1-C_6-alkyl, C_3-C_8-cycloalkyl, C_1-C_6-haloalkyl, C_1-C_6-alkoxy, C_1-C_6-alkoxy-C_1-C_6-alkoxy, C_1-C_6-haloalkoxy, C_3-C_8-cycloalkoxy, C_1-C_6-alkylamino, di-C_1-C_6-alkylamino, C_1-C_6-alkylsulfonyl, phenyl, phenoxy, 5- or 6-membered heterocyclyl, containing one, two or three heteroatoms, selected from O, N and S as ring members, and 5- or 6-membered heterocyclyloxy, containing one, two or three heteroatoms, selected from O, N and S as ring members, wherein R^f and R^g are independently from each other selected from H, C_1-C_6-alkyl, C_1-C_6-haloalkyl, C_3-C_8-cycloalkyl, C_3-C_8-cycloalkenyl and 5- or 6-membered heterocyclyl, containing one, two or three heteroatoms, selected from O, N and S as ring members, or R^f and R^g together with the nitrogen atom to which they are bound form a cyclic amine, which may comprise a further heteroatom selected from O, N and S as a ring member and/or

wherein two radicals bound to the same carbon atom of the C_3-C_8-cycloalkyl or heterocyclyl moieties in the aforementioned radicals Y together with said carbon atom may form a carbonyl group and/or

wherein the C_3-C_8-cycloalkyl, phenyl, naphthyl or heterocyclyl moieties in the aforementioned radicals Y may carry a fused carbocyclic moiety, selected from C_3-C_8-cycloalkyl, C_3-C_8-cycloalkenyl and benzene, or a fused heterocyclic moiety, wherein the heterocyclic moiety is selected from 5- to 7-membered heterocyclic radicals and 5- to 10-membered, bicyclic heterocyclic radicals, containing one, two or three heteroatoms, selected from O, N and S as ring membersm and wherein said fused carbocyclic or heterocyclic moiety is unsubstituted or carries at least one substituent selected from hydroxy, halogen, cyano, nitro, C_1-C_6-alkyl, C_3-C_8-cycloalkyl, C_1-C_6-haloalkyl, C_1-C_6-alkoxy, C_1-C_6-haloalkoxy, C_1-C_6-alkylamino, di-C_1-C_6-alkylamino, C_1-C_6-alkylsulfonyl, phenyl and 5- or 6-membered hetaryl and/or
wherein two radicals bound to the same carbon atom of the fused carbocyclic

or heterocyclic moiety together with said carbon atom may form a carbonyl group; and wherein

R^1 and R^2 independently from each other are selected from C_1-C_6-alkyl, C_3-C_8-cycloalkyl, phenyl and naphthyl, wherein

C_1-C_6-alkyl in the aforementioned radicals R^1 and R^2 is unsubstituted or carries at least one substituent selected from hydroxy, halogen, cyano, nitro, C_1-C_6-alkoxy, C_1-C_6-haloalkoxy, C_1-C_6-alkylamino, di-C_1-C_6-alkylamino and C_1-C_6-alkylsulfonyl and/or

wherein two radicals bound to the same carbon atom of said C_1-C_6-alkyl in the aforementioned radicals R^1 and R^2 together with said carbon atom may form a carbonyl group, and wherein

the C_3-C_8-cycloalkyl, phenyl and naphthyl moieties in the aforementioned radicals R^1 and R^2 are unsubstituted or carry at least one substituent selected from hydroxy, halogen, cyano, nitro, C_1-C_6-alkyl, C_3-C_8-cycloalkyl, C_1-C_6-haloalkyl, C_1-C_6-alkoxy, C_1-C_6-haloalkoxy, C_1-C_6-alkylamino, di-C_1-C_6-alkylamino, C_1-C_6-alkylsulfonyl, phenyl and 5- or 6-membered hetaryl and/or

wherein two radicals bound to the same carbon atom of said C_3-C_8-cycloalkyl moieties of the radicals R^1 and R^2 together with said carbon atom may form a carbonyl group.

In a second aspect, there is provided pyrazole compounds of formula (I) as defined above as medicaments.

In a third aspect, there is provided the use of pyrazole compounds of formula (I) as defined above for preparing a medicament for the prevention and/or treatment of inflammatory, infectious and immunoregulatory disorders, respiratory or gastrointestinal diseases or complaints, inflammatory diseases of the joints and allergic diseases of the nasopharynx, eyes, and skin.

In a fourth aspect, there is provided pharmaceutical formulations, containing one or more of the pyrazole compounds of formula (I) as defined above.

In a fifth aspect, there is provided pharmaceutical formulations, containing one or more pyrazole compounds of formula (I) as defined above in combination with one or more active substances selected from among betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, CCR3 antagonists, CCR5 antagonists, CCR9 antagonists, 5-LO inhibitors, histamine-receptor antagonists, SYK inhibitors and sulfonamides.